Group 1 - The company, Heng Rui Medicine, stated that it regularly discloses the number of shareholders as required [1] - Investors are advised to pay attention to the relevant content in the periodic reports [1]

Group 1 - JPMorgan increased its stake in Heng Rui Medicine (01276) by 1,127,828 shares at a price of HKD 74.6126 per share, totaling approximately HKD 84.15 million [1] - After the increase, JPMorgan's total shareholding in Heng Rui Medicine is approximately 19.194 million shares, representing a holding percentage of 7.43% [1]

Group 1 - The core point of the article is that JPMorgan has increased its stake in Heng Rui Medicine (600276) by purchasing 112,782.8 shares at a price of 74.6126 HKD per share, totaling approximately 84.15 million HKD [1] - After the purchase, JPMorgan's total holdings in Heng Rui Medicine amount to approximately 19.194 million shares, representing a holding percentage of 7.43% [1]

（编辑 丛可心） 证券日报网讯 1月9日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新与国际化两大 发展战略，创新成果转化高效赋能，创新药销售引领业绩增长。2025年上半年，公司创新药销售及许可 收入95.61亿元，占公司营业收入比重60.66%。此外，公司自2023年以来达成12笔创新成果对外授权， 潜在总交易额超270亿美元。公司将继续大力推进"科技创新"和"国际化"两大发展战略，稳步推进研发 创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管 线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。 ...

证券日报网讯1月9日，恒瑞医药（600276）在互动平台回答投资者提问时表示，二级市场股价受宏观经 济、市场情绪等多重因素影响。公司将继续大力推进"科技创新"和"国际化"两大发展战略，稳步推进研 发创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品 管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好地发展回馈股东。 ...

Core Viewpoint - Heng Rui Medicine (600276) is strategically expanding its presence across multiple therapeutic areas, focusing on long-term diversified growth through a robust R&D pipeline in oncology and other fields [1] Group 1: Strategic Development - The company has a comprehensive layout in various treatment areas, including oncology, metabolic and cardiovascular diseases, immunology, respiratory diseases, and neuroscience [1] - Heng Rui Medicine is committed to a differentiated R&D strategy that is guided by clinical needs, utilizing advanced technology platforms to develop a highly differentiated innovative product matrix [1] Group 2: Global Expansion and Collaboration - The company plans to accelerate its global expansion steadily and deepen external collaborations to enhance its overseas R&D capabilities [1] - There is a focus on strengthening commercialization capabilities in both domestic and international markets to maximize the global market potential of high-quality innovative products [1]

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of HRS-5965 capsules, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) [1][2] Group 1: Company Developments - The application for HRS-5965's market approval is based on a pivotal study involving PNH patients who had not previously received complement inhibitor treatment [1] - The clinical study (HRS-5965-301) was a Phase III trial comparing HRS-5965 capsules with Eculizumab in treating PNH patients, led by prominent researchers from the Chinese Academy of Medical Sciences [1] - The study included 76 patients across 13 centers nationwide, showing that HRS-5965 significantly improved hemoglobin levels, reduced the need for blood transfusions, and enhanced quality of life compared to Eculizumab [1] Group 2: Industry Context - PNH is a rare acquired hemolytic disease characterized by the deficiency of CD55 and CD59, leading to complement-mediated intravascular hemolysis, and has been included in the national rare disease directory due to its low incidence/prevalence [2] - HRS-5965 capsules act as a complement factor B inhibitor, which can suppress complement-mediated hemolysis and improve hemoglobin levels [2] - Currently, the only other drug targeting this indication is Novartis's Iptacopan (Fabhalta), which is projected to generate global sales of approximately $129 million in 2024 [2] - The cumulative R&D investment for HRS-5965 capsules has reached approximately 218 million yuan [2]

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received a notice of acceptance from the National Medical Products Administration for the market approval application of HRS-5965 capsules, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) [1][2] Group 1: Product Development - The application for HRS-5965 is based on a pivotal study involving PNH patients who had not previously received complement inhibitor treatment [1] - The study, HRS-5965-301, is a Phase III clinical trial comparing HRS-5965 capsules with Eculizumab in treating PNH patients, involving 76 patients across 13 centers in China [1] - Results indicate that HRS-5965 significantly improves hemoglobin levels, reduces the need for blood transfusions, and alleviates fatigue compared to Eculizumab, enhancing patients' quality of life [1] Group 2: Market Context - PNH is a rare acquired hemolytic disease characterized by the deficiency of CD55 and CD59, leading to complement-mediated intravascular hemolysis [2] - HRS-5965 is a complement factor B inhibitor that can suppress complement-mediated hemolytic reactions and improve hemoglobin levels [2] - Currently, the only approved drug targeting this indication is Novartis's Iptacopan (Fabhalta), with projected global sales of approximately $129 million in 2024 [2] - The cumulative R&D investment for HRS-5965 has reached approximately 218 million yuan [2]

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of HRS-5965 capsules, indicating progress in the drug approval process for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in adult patients [1]. Group 1 - The drug name is Fumaric Acid Likanopam Capsules [1] - The dosage form is capsule [1] - The acceptance number for the application is CXHS2600014 [1] - The application is currently in the marketing phase [1] - The applicant is Chengdu Shengdi Pharmaceutical Co., Ltd. [1] - The intended indication is for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1]

Core Insights - 恒瑞医药 has received approval from the National Medical Products Administration for clinical trials of several new drugs, including SHR-4394, HRS-5041, Zemeituzumab, and Rivolumab [1][2] Group 1: Drug Approvals and Clinical Trials - The company has been granted approval to conduct clinical trials for SHR-4394, a self-developed biopharmaceutical aimed at treating prostate cancer, with a total R&D investment of approximately 38.4 million yuan [1] - HRS-5041 is a new, efficient, and selective AR PROTAC small molecule also targeting prostate cancer, with a total R&D investment of about 92.66 million yuan [1] - Zemeituzumab is a novel oral EZH2 inhibitor approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in adults, with a total R&D investment of around 217 million yuan [2] - Rivolumab is a second-generation AR inhibitor approved for treating high-burden metastatic hormone-sensitive prostate cancer, with a total R&D investment of approximately 697 million yuan [2] Group 2: Market Context and Competitors - Currently, there are no approved products in the market for SHR-4394 and HRS-5041, indicating a potential first-mover advantage for the company [1] - Zemeituzumab faces competition from Tazemetostat and Valemetostat, which are already approved in the market, with Tazemetostat projected to generate global sales of about 51 million dollars in 2024 [2] - Rivolumab competes with several second-generation AR inhibitors, including Enzalutamide, Apalutamide, and Darolutamide, with projected global sales of similar products reaching approximately 11.037 billion dollars in 2024 [2]